VEGFA and Hypertension: In particular, more patients in the older group (e.g., >65 years) experienced specific VEGF-related AEs of grade 3 or higher during MTKI treatment than did younger patients (e.g., lenvatinib-emergent hypertension: 49.1% vs. 36.8%, proteinuria: 13.2% vs. 7.7%, respectively).